Sanofi-Aventis 3Q09
3Q Revenues: $10.8 billion (+8%)
3Q Earnings:$3.3 billion (+16%)
YTD Revenues: $32.0 billion (+7%)
YTD Earnings: $6.7 billion (+20%)
Comments: Pharmaceutical sales were up 6% to $9.3 billion in the quarter and YTD sales rose 4% to $28.5 billion. Exchange rates favorably effected results by 2% and 3%, respectively. Lovenox and Lantus sales reached $1.1 billion, up 14% and 22%, respectively. Plavix sales were $968.9 million (+4%). Apidra sales were up 32% in the quarter to $49.6 million. Sales of Eloxatin were $281.6 million (-44%) due to generic competition. The company launched Multaq, an anti-arrhythmic, in the U.S. with sales of $19.0 million. Human Vaccines revenue rose 5% to $1.5 billion, driven by the performance of Pentacel, Pentaxim and Menactra, as well as the first H1N1 shipments.
Magazine
